Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1018068 | 0.89 | MAPT (0.50) | MAPTCYP19A1CA2CA12CA1 | |
| SCHEMBL9672257 | 0.84 | ALDH1A1 (0.58) | MAPTCA2ALDH1A1CYP2C19CYP3A4 | |
| SCHEMBL1020576 | 0.82 | CA2 (0.61) | MAPTCYP19A1CA2CA12CA1 | |
| SCHEMBL13423489 | 0.81 | MAPT (0.53) | MAPTCYP19A1CA2CA12CA1 | |
| SCHEMBL10409572 | 0.78 | MAPT (0.50) | MAPTCYP19A1CA2CA12CA1 | |
| SCHEMBL5316692 | 0.78 | MAPT (0.50) | MAPTCYP19A1CA2CA12CA1 | |
| SCHEMBL1014212 | 0.78 | CA2 (0.58) | MAPTCYP19A1CA2CA12CA1 | |
| SCHEMBL2098230 | 0.78 | CYP19A1 (0.50) | MAPTCYP19A1CA2CA12CA1 | |
| SCHEMBL5387555 | 0.77 | PLCG1 (0.59) | CA2ALDH1A1CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL11335931 | 0.76 | MAPT (0.42) | MAPTCYP19A1CA2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20210070707-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200190030-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-20180258043-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2018-09-13 | — | — | US | disclosed |
| US-20180029984-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-9790183-B2 | Pyridyl inhibitors of hedgehog signalling | GENENTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170015627-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2017-01-19 | — | — | US | disclosed |
| US-20160152569-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-9321761-B2 | Pyridyl inhibitors of hedgehog signalling | CURIS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| EP-1328526-A1 | 3,8-DIAZABICYCLO[3.2.1]OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2003-07-23 | — | — | EP | disclosed |
| US-6559162-B2 | Electrophysiological activity | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| US-6559143-B1 | Class III electrophysiological activity, drugs which prolong the trans-membrane action potential duration and refractoriness, without affecting cardiac conduction | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| EP-1244631-A1 | NEW AZABICYCLOOCTANE DERIVATIVES USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-10-02 | — | — | EP | disclosed |
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
| EP-1235831-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2002060902-A1 | 3,7-DIAZABICYCLO[3.3.0]OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | WO | disclosed |
| WO-2002032902-A1 | 3,8-DIAZABICYCLO[3.2.1]OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-04-25 | — | — | WO | disclosed |
| WO-2001047893-A1 | NEW AZABICYCLOOCTANE DERIVATIVES USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
| WO-2001028992-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190030-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | MAPT 3822/4885CYP19A1 3751/4885CA2 3856/4885 |
| US-20160152569-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | MAPT 3822/4885CYP19A1 3751/4885CA2 3856/4885 |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | MAPT 3822/4885CYP19A1 3751/4885CA2 3856/4885 |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | SHH, GLI1, SMO | MAPT 3696/4885CYP19A1 3863/4885CA2 3954/4885 |
| US-20180029984-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | MAPT 3822/4885CYP19A1 3751/4885CA2 3856/4885 |
| US-20210070707-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | MAPT 3822/4885CYP19A1 3751/4885CA2 3856/4885 |
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | KCNH1, KCNH2, KCNH3 | MAPT 4857/4885CYP19A1 187/4885CA2 2353/4885 |
| US-20180258043-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | MAPT 3822/4885CYP19A1 3751/4885CA2 3856/4885 |
| US-20170015627-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | MAPT 3822/4885CYP19A1 3751/4885CA2 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.